Brest, Patrick http://orcid.org/0000-0002-1252-4747
Refae, Sadal
Mograbi, Baharia http://orcid.org/0000-0002-1025-3429
Ferrero, Jean-Marc http://orcid.org/0000-0003-0069-3743
Bontoux, Christophe http://orcid.org/0000-0001-5446-6197
Hofman, Paul http://orcid.org/0000-0003-0431-9353
Milano, Gerard http://orcid.org/0000-0003-2478-0040
Funding for this research was provided by:
Agence Nationale de la Recherche (ANR-15-IDEX-01, R19162DD)
Canceropôle PACA
Fondation ARC pour la Recherche sur le Cancer
Article History
Received: 10 March 2022
Revised: 30 March 2022
Accepted: 1 April 2022
First Online: 6 May 2022
Competing interests
: PB and BM declare no financial ties with any organisation that might have an interest in the submitted work over the previous 3 years and no other relationships or activities that could appear to have influenced the submitted work. GM has received honoraria from MERCK, Bristol Myers Squibb (BMS) for lectures specifically on the covered subject. PH has received honoraria from AstraZeneca, BMS, MSD, Lilly, Bayer, Pfizer, ThermoFisher, Roche, Illumina, Novartis, Biocartis, Janssen and Abbvie for lectures, consulting fees and membership on their advisory board.
: Not applicable for this comment.